2.10Open2.20Pre Close1 Volume87 Open Interest20.00Strike Price210.00Turnover8332.28%IV-3.47%PremiumOct 18, 2024Expiry Date2.70Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8648Delta0.1005Gamma6.07Leverage Ratio-282.9205Theta0.0000Rho-5.25Eff Leverage0.0001Vega
Boxman : Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company’s Cardiac Surgery System to successfully treat two patients with atrial fibrillation at St. Antonius Hospital, Nieuwegein, The Netherlands. Dr. Van Putte was joined by colleagues and Pulse Biosciences’ Chief Medical Officer, Cardiac Surgery, Dr. Gan Dunnington and Chief Science Officer, Cardiac Surgery, Dr. Niv Ad during the concomitant procedure. The first-in-human feasibility study is a multicenter study of up to 30 patients that will include an endocardial catheter-based remapping to confirm chronic isolation at approximately three months post treatment